NCT06450912Completed
Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction
WSI Ratio as a Biomarker for Mechanical Complication of Hemorrhagic MI
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Wall motion index ratio is an important parameter to determine regions of high vulnerability within the 17-segment LV model of hemorrhagic MI.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 250 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 1 Jun 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Rohan Dharmakumar
- Diseases
- Coronary artery disease
- NCT number
- NCT06450912
What you commit to
- Study type: Observational
- Participants enrolled: 250
- From 1 Jun 2022 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication to CMR (Contrast Hypersensitivity, Metallic Implants, Abnormal Rhythms, breathing difficulties)
Who the study is looking for
- Index STEMI
- Primary PCI
- Able to complete Cardiac MR - STRAIN Protocol
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Krannert Cardiovascular Research Center, Indiana University School of Medicine Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.